the U.S. Food and Drug Administration approves Farxiga (dapagliflozin) for adults with heart failure.
FDA
Heart failure occurs when the heart does not pump enough blood to support the body’s needs. Farxiga is approved to treat class II-IV heart failure with reduced ejection fraction. Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. The clinical trial shows improved survival and reduced the need for hospitalization in adults with heart failure.
Farxiga is also FDA-approved to improve glycemic control in adults with type 2 diabetes.